Biomarker: M005-IgE Candida albicans

Overview

M005-IgE Candida albicans measures allergen-specific immunoglobulin E (IgE) antibodies directed against Candida albicans antigens in blood. C. albicans is a yeast that can colonize humans and, in some individuals, may be associated with IgE-mediated hypersensitivity. A high result indicates sensitization to the tested Candida extract but does not by itself prove symptomatic allergy, active infection, or predict reaction severity. The test may support evaluation of selected patients with suspected fungal hypersensitivity, particularly in the context of compatible allergic or dermatologic symptoms.

Clinical Use Cases

Support evaluation of suspected C. albicans sensitization in patients with compatible allergic symptoms.
Complement clinical assessment of atopic dermatitis when fungal hypersensitivity is being considered.
Support investigation of suspected Candida-associated hypersensitivity in selected patients with recurrent vulvovaginal symptoms, although evidence is limited and specific IgE may be normal in some affected patients.
Contribute to research on fungal sensitization in asthma, atopic disease, urticaria, and other hypersensitivity conditions.
Provide an alternative to skin testing when skin testing is unsuitable because of skin disease, medication use, or concern about provoking a reaction.

Specimen Types

Venous blood, typically collected as serum.
Plasma may be accepted by some measurement systems, depending on the assay.

Measurement Methods

In vitro allergen-specific IgE immunoassay.
Enzyme-linked immunosorbent assay, or ELISA.
Fluorescent or chemiluminescent solid-phase immunoassays.
Historically, radioallergosorbent testing, or RAST, and related immunoassays.

Test Preparation and Influencing Factors

Fasting is generally not required.
Patients should report antihistamines and other medications. Medication changes should be made only when directed by a healthcare professional.
Results should be interpreted with the clinical history and examination because sensitization does not necessarily indicate clinically relevant allergy.
The amount of specific IgE does not reliably predict the severity of a reaction.
Total IgE elevation, smoking, parasitic infection, and other allergic or inflammatory conditions may complicate interpretation of IgE results.
Assay platforms, allergen extracts, reporting units, and decision thresholds may differ between laboratories.
A negative result does not completely exclude localized or non-IgE-mediated hypersensitivity.
Recent antifungal treatment or changes in exposure may affect clinical symptoms, but they do not provide a standardized reason to delay blood collection.